COPENHAGEN, March 7 (Reuters) - Novo Nordisk

will increase its capital expenditure to build its fill-finish

capacity if the company does not close the planned Catalent ( CTLT )

acquisition, the Danish drugmaker's Chief Financial

Officer Karsten Munk Knudsen said on Thursday.

Novo would also do more deals with contract drugmakers if

the company does not complete the Catalent ( CTLT ) purchase, Knudsen

told analysts at Novo's capital markets day.